Schizophrenia  >>  GSK1034702  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK1034702 / GSK
NCT00743405: Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects

Completed
1
30
Europe
GSK1034702, Placebo
GlaxoSmithKline
Cognitive Disorders
12/08
12/08
NCT00937846: Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study

Completed
1
4
Europe
GSK1034702
GlaxoSmithKline
Cognitive Disorders
08/09
08/09
NCT01371799: A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers

Completed
1
9
Europe
Drug
GlaxoSmithKline
Mental Disorders
06/10
06/10

Download Options